Working With Alimentiv

Leveraging 30+ years of global experience and expertise in GI clinical trials, **Alimentiv** has an unparalleled understanding of the GI therapeutic landscape and current practices.

Our established partnerships and scientific leadership make us the trusted CRO for full-service GI clinical trials.

Monitoring & Site Management Track Record

We provide global monitoring services, delivered by seasoned GI monitoring experts:

- Average CRA experience: **10+ years**
- Extensive GI training
- Low CRA turnover rates

Alimentiv's Therapeutic Focus

Alimentiv stands at the forefront of patient recruitment and imaging innovations for gastrointestinal and liver diseases. We drive health breakthroughs through advanced research, accelerated clinical trials, and delivering actionable biomarker insights.

Key Indications

- **Inflammatory bowel disease (IBD):** Ulcerative colitis (UC) and Crohn's disease (CD), fibrostenosing Crohn's disease, pouchitis
- **Eosinophilic gastrointestinal diseases (EGIDs):** Eosinophilic esophagitis (EoE)
- **Microscopic colitis**
- **Celiac disease (CeD)**
- **Functional and motility disorders of the gastrointestinal tract:** Gastroperesis
- **Familial adenomatous polyposis (FAP)**
- **Inflammatory liver conditions:** Primary sclerosing cholangitis (PSC), primary biliary cholangitis (PBC)

Contact us to learn more or to join the Alimentiv Site Network:
asn@alimentiv.com

alimentiv™

Canada
800 Collip Circle
Suite 104 London, Ontario
Canada N6G 4X8

USA
6220 Greenwich Dr.
Suite 101, San Diego
California, USA 92122

Europe
Hullenbergweg 278-308
Vogelstruys Building
1101 BV Amsterdam

Australia
Suite 6, Level 2
29-31 Lexington Drive
Bella Vista NSW 2153

alimentiv™
discovery accelerated.™

Partner With Our **Global Site Network**

alimentiv.com/site-network

GI IS OUR WHY

We are a global GI-focused contract research organization (CRO) providing clinical trial, core medical imaging, precision medicine, and real-world evidence services to pharmaceutical and biotechnology industries.

Our core therapeutic focus includes **inflammatory bowel disease (IBD), EGID, celiac disease,** and **liver diseases.**

We Are Global

With headquarters in **London, ON, Canada,** and 500+ experienced employees across **North America, Europe, LATAM** and **APAC,** we ensure global site coverage and unparalleled support for our sites.

Over the last 5 years, Alimentiv has conducted **35+ full-service GI clinical studies,** spanning phases 1 – 4.

Full-Service Studies

- Crohn's disease
- Ulcerative colitis
- Eosinophilic esophagitis
- Fistulizing CD
- Hepatic impairment
- Pediatric Crohn's disease
- Pouchitis
- Renal impairment

Our Science

Alimentiv is committed to science through:

- Outcomes development
- Design & conduct of Alimentiv-sponsored studies
- Publication & presentation of research
- Participation in scientific consortiums
- Leadership & participation in advisory boards
- Clinical Trial Fellowship program

Medical R&D Expertise:

Vipul Jairath, MD Chief Medical Officer	**Chris Ma, MD** Senior Medical Director
Gabriela Radulescu, MD VP, MR&D	**Geert D'Haens, MD** Scientific Advisor
Wendy Teft, PhD VP, AcelaBio	**Juan Pablo Arab, MD** Scientific Advisor
GY Zou, PhD Biostatistician Director	**Remo Panaccione, MD** Scientific Advisor

How We Support Our Sites:

- Our CRAs and other project team members are GI clinical trial experts and receive rigorous ongoing training to ensure **consistency** of knowledge and experience.
- Support project teams with our **expert scientific leaders.**
- Provide training and **follow-up support** for principal investigators and site staff.
- Employ **local experts** familiar with country/language-specific submission processes and regulatory knowledge for each site.
- Support site activities via dedicated and highly **experienced project managers** and **clinical operation leads.**
- Ensure protocols offered to your sites match your interest, experience and capabilities.
- Apply efficiencies in our start-up and overall clinical trial processes to **alleviate the sites burden.**
- Ensure **long-term relationships** are built between the CRA and site team with low CRA turnover rates.
- Focus on the development of patient and site centric solutions (e.g. e-diaries and e-consent) to **support our sites** and alleviate the site burden.
- Regular interactions and support from the Site Engagement team through **in-person** and **online** meetings to keep us connected with our sites and informed about the latest developments at your site and in the overall GI clinical trial landscape.